Fact CheckerSign in

NCT06960577RecruitingPhase 2

Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)

An Open-label, Single-arm, Global Study of Perioperative Durvalumab With Cisplatin-based Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)

Source: ClinicalTrials.gov · Last updated 8 Oct 2026

Brief summary (registry, in English)

The Phase II NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with cisplatin based neoadjuvant chemotherapy in a clinical practice setting.

Status (registry)
Recruiting
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
150 (estimated)
First submitted
29 Apr 2025
Start date
15 May 2025
Primary completion date
30 Aug 2028
Lead sponsor
AstraZeneca
NCT number
NCT06960577
EU CT number
2024-519246-75-01

What you commit to

  • Study type: Interventional · Phase 2
  • Planned participants: 150
  • From 15 May 2025 to the primary completion date, 30 Aug 2028
  • 58 sites in 7 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Prior exposure to immune-mediated therapy including, but not limited to, other anti CTLA-4, anti-PD 1, anti-PD L1 and anti-PD-L2 antibodies, excluding Bacillus Calmette-Guérin
  • Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab
  • Any concomitant medication known to be contraindicated with ddMVAC.

Other illness

  • Evidence of lymph node (N2-N3) or metastatic (M1) disease
  • Uncontrolled intercurrent illness.

Other

  • Inoperable tumour(s) with fixation to the pelvic wall on clinical examination

Who the study is looking for

  • Participants with clinical tumour stage T2-T4aN0/1M0 or T1N1M0 with transitional or mixed transitional cell histology
  • Participants must be planning to undergo radical cystectomy
  • Participants who have not received prior systemic chemotherapy or immunotherapy for treatment of muscle-invasive bladder cancer
  • ECOG performance status of 0 or 1
  • Minimum life expectancy of 12 weeks at first dose of study medication

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (58)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
-
Coordinator of this site? Confirm its status
ChermsideAustraliaRecruiting
-
Coordinator of this site? Confirm its status
Elizabeth ValeAustraliaRecruiting
-
Coordinator of this site? Confirm its status
HeidelbergAustraliaRecruiting
-
Coordinator of this site? Confirm its status
Hong KongAustraliaRecruiting
-
Coordinator of this site? Confirm its status
KogarahAustraliaRecruiting
-
Coordinator of this site? Confirm its status
Macquarie UniversityAustraliaRecruiting
-
Coordinator of this site? Confirm its status
MurdochAustraliaRecruiting
-
Coordinator of this site? Confirm its status
Port MacquarieAustraliaWithdrawn
-
Coordinator of this site? Confirm its status
St LeonardsAustraliaRecruiting
-
Coordinator of this site? Confirm its status
BarretosBrazilRecruiting
-
Coordinator of this site? Confirm its status
JaúBrazilWithdrawn
-
Coordinator of this site? Confirm its status
NatalBrazilWithdrawn
-
Coordinator of this site? Confirm its status
Porto AlegreBrazilRecruiting
-
Coordinator of this site? Confirm its status
Rio de JaneiroBrazilWithdrawn
-
Coordinator of this site? Confirm its status
Santo AndréBrazilRecruiting
-
Coordinator of this site? Confirm its status
São José do Rio PretoBrazilWithdrawn
-
Coordinator of this site? Confirm its status
São PauloBrazilRecruiting
-
Coordinator of this site? Confirm its status
HamiltonCanadaRecruiting
-
Coordinator of this site? Confirm its status
LondonCanadaRecruiting
-
Coordinator of this site? Confirm its status
MontrealCanadaRecruiting
-
Coordinator of this site? Confirm its status
OttawaCanadaWithdrawn
-
Coordinator of this site? Confirm its status
QuébecCanadaRecruiting
-
Coordinator of this site? Confirm its status
SherbrookeCanadaRecruiting
Hospital del Mar
Coordinator of this site? Confirm its status
BarcelonaSpainRecruiting
Hospital de la Santa Creu i Sant Pau
Coordinator of this site? Confirm its status
BarcelonaSpainRecruiting
Vall d'Hebron Institute of Oncology
Coordinator of this site? Confirm its status
BarcelonaSpainRecruiting
Hospital Clinic de Barcelona
Coordinator of this site? Confirm its status
BarcelonaSpainRecruiting
Institut Català d'Oncologia
Coordinator of this site? Confirm its status
GironaSpainRecruiting
Complejo Hospitalario Universitario Insular Materno Infantil
Coordinator of this site? Confirm its status
Las Palmas de Gran CanariaSpainRecruiting
Hospital Universitario Lucus Augusti
Coordinator of this site? Confirm its status
LugoSpainRecruiting
Hospital Clínico San Carlos
Coordinator of this site? Confirm its status
MadridSpainRecruiting
MD Anderson Cancer Center
Coordinator of this site? Confirm its status
MadridSpainRecruiting
Complexo Hospitalario Universitario De Santiago
Coordinator of this site? Confirm its status
Santiago de CompostelaSpainRecruiting
Institut de Cancerologie de L'Ouest
Coordinator of this site? Confirm its status
AngersFranceRecruiting
Institut Bergonie
Coordinator of this site? Confirm its status
BordeauxFranceRecruiting
Centre Hospitalier Universitaire De Bordeaux
Coordinator of this site? Confirm its status
Bordeaux CedexFranceRecruiting
Centre D'Oncologie Et de Radiotherapie 37
Coordinator of this site? Confirm its status
Chambray-lès-ToursFranceRecruiting
Centr Georges Francois Leclerc
Coordinator of this site? Confirm its status
DijonFranceRecruiting
Centre Hospitalier Universitaire de Lille
Coordinator of this site? Confirm its status
LilleFranceRecruiting
Centre Leon Berard
Coordinator of this site? Confirm its status
LyonFranceRecruiting
Institut Paoli-Calmettes
Coordinator of this site? Confirm its status
MarseilleFranceRecruiting
Centre De Cancerologue Du Grand Montpellier
Coordinator of this site? Confirm its status
MontpellierFranceRecruiting
Centre Antoine Lacassagne
Coordinator of this site? Confirm its status
Nice Cedex 2FranceRecruiting
Institut de Cancérologie du Gard
Coordinator of this site? Confirm its status
NîmesFranceRecruiting
Hopital Européen George Pompidou
Coordinator of this site? Confirm its status
ParisFranceRecruiting
Hopital Saint Louis
Coordinator of this site? Confirm its status
ParisFranceRecruiting
Hospices Civils de Lyon
Coordinator of this site? Confirm its status
Pierre-BéniteFranceRecruiting
Centre Hospitalier Universitaire de Poitiers
Coordinator of this site? Confirm its status
PoitiersFranceRecruiting
Capio La Croix Du Sud
Coordinator of this site? Confirm its status
Quint-FonsegrivesFranceRecruiting
Centre De Lutte Contre Le Cancer Eugene Marquis
Coordinator of this site? Confirm its status
Rennes CedexFranceRecruiting
Centre Hospitalier Universitaire Rouen
Coordinator of this site? Confirm its status
Rouen CedexFranceRecruiting
Les Hopitaux Universitaires De Strasbourg
Coordinator of this site? Confirm its status
Strasbourg Cedex 2FranceRecruiting
Hospital Foch
Coordinator of this site? Confirm its status
SuresnesFranceRecruiting
Azienda Ospedaliero-Universitaria Careggi
Coordinator of this site? Confirm its status
FlorenceItalyRecruiting
Azienda Ospedaliero-Universitaria San Luigi Gonzaga
Coordinator of this site? Confirm its status
OrbassanoItalyRecruiting
I.F.O. Istituti Fisioterapici Ospitalieri
Coordinator of this site? Confirm its status
RomeItalyRecruiting
Netherlands Cancer Institute
Coordinator of this site? Confirm its status
AmsterdamNetherlandsRecruiting
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Coordinator of this site? Confirm its status
RotterdamNetherlandsRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.